No Data
No Data
Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $460
Vertex Pharmaceuticals Analyst Ratings
Vertex Pharmaceuticals Incorporated (VRTX) Slid Due to Setbacks In Clinical Trials
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $460
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Cuts Target Price to $456